News
- Author:
- Neil Osterweil
Publish date: September 25, 2018
Nearly two-thirds of evaluable patients with mantle cell lymphoma had durable responses to induction and maintenance.
News
- Author:
- Neil Osterweil
Publish date: September 24, 2018
The thrombopoietin-receptor agonist’s iron-chelating action stimulates hematopoietic stem cell activity, independent of the thrombopoietin receptor...
News
- Author:
- Neil Osterweil
Publish date: September 21, 2018
Women with detectable plasma human papillomavirus DNA at the end of chemoradiation were at increased risk for recurrence.
News
- Author:
- Neil Osterweil
Publish date: September 19, 2018
Cardiac and neurologic toxicities accounted for nearly half of all toxicities associated with cancer therapy with immune checkpoint inhibitors.
News
- Author:
- Neil Osterweil
Publish date: September 19, 2018
Preclinical research suggests an AKT inhibitor could be effective against multiple myeloma (MM).
The inhibitor, HS1793, is a derivative of the anti...
News
- Author:
- Neil Osterweil
Publish date: September 18, 2018
Patients with renal cell carcinoma who had higher serum levels of C-reactive protein had worse cancer-specific survival.
News
- Author:
- Neil Osterweil
Publish date: September 18, 2018
Gene sequencing early after transplant may provide important prognostic information in patients with myelodysplastic syndromes (MDS), according to ...
News
- Author:
- Neil Osterweil
Publish date: September 14, 2018
Of 41 patients with metastatic kidney cancer treated with denosumab and a tyrosine kinase inhibitor, 7 developed osteonecrosis of the jaw.
News
- Author:
- Neil Osterweil
Publish date: September 13, 2018
Vitiligo, rash, nail changes, and other cutaneous toxicities are associated with good clinical outcomes with three major classes of cancer therapie...
News
- Author:
- Neil Osterweil
Publish date: September 12, 2018
The investigational agent showed multiple myeloma-specific cytotoxicity in human cells, and antimyeloma activity in mouse models.
News
- Author:
- Neil Osterweil
Publish date: September 12, 2018
The presence of one or more mutations with higher maximum variant allele frequency 30 days after transplant heralded worse outcomes.
News
- Author:
- Neil Osterweil
Publish date: September 10, 2018
Long-term results of a phase 3 trial indicate that concurrent FEC, paclitaxel and trastuzumab is not warranted, investigators say.
News
- Author:
- Neil Osterweil
Publish date: September 6, 2018
Fluorescent indocyanine green under near infrared spotted significantly more lymph nodes in patients with cancer than isosulfan blue under white li...
News
- Author:
- Neil Osterweil
Publish date: September 6, 2018
The ESMO Scale of Clinical Actionability for Molecular Targets is intended to help oncologists prioritize therapeutic targets detected on gene pane...
News
- Author:
- Neil Osterweil
Publish date: September 6, 2018
The findings could enhance confidence in observation/active surveillance as a management strategy for men with low-risk prostate cancer.
